Wall Street brokerages forecast that Constellation Pharmaceuticals Inc (NASDAQ:CNST) will post ($0.70) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Constellation Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.80) and the highest is ($0.61). Constellation Pharmaceuticals reported earnings per share of ($0.77) in the same quarter last year, which indicates a positive year-over-year growth rate of 9.1%. The business is scheduled to announce its next quarterly earnings report on Thursday, March 12th.
On average, analysts expect that Constellation Pharmaceuticals will report full year earnings of ($2.98) per share for the current year, with EPS estimates ranging from ($3.07) to ($2.80). For the next financial year, analysts anticipate that the business will post earnings of ($3.06) per share, with EPS estimates ranging from ($4.19) to ($2.15). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Constellation Pharmaceuticals.
Several research analysts recently commented on the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a $40.00 price target (up previously from $17.00) on shares of Constellation Pharmaceuticals in a research note on Thursday, November 7th. BMO Capital Markets downgraded shares of Constellation Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their target price for the company from $43.00 to $42.00 in a research report on Thursday, January 9th. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Constellation Pharmaceuticals in a research report on Tuesday, December 10th. Zacks Investment Research downgraded shares of Constellation Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday. Finally, SunTrust Banks began coverage on shares of Constellation Pharmaceuticals in a research report on Thursday, February 13th. They set a “buy” rating and a $50.00 target price on the stock. Two research analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $44.09.
A number of hedge funds and other institutional investors have recently bought and sold shares of CNST. Meeder Asset Management Inc. bought a new stake in shares of Constellation Pharmaceuticals in the 4th quarter valued at about $36,000. Victory Capital Management Inc. boosted its holdings in shares of Constellation Pharmaceuticals by 43.4% in the 4th quarter. Victory Capital Management Inc. now owns 2,199 shares of the company’s stock valued at $73,000 after buying an additional 666 shares in the last quarter. Bank of Montreal Can boosted its holdings in shares of Constellation Pharmaceuticals by 43.0% in the 4th quarter. Bank of Montreal Can now owns 1,937 shares of the company’s stock valued at $91,000 after buying an additional 582 shares in the last quarter. Citigroup Inc. boosted its holdings in shares of Constellation Pharmaceuticals by 267.6% in the 4th quarter. Citigroup Inc. now owns 3,099 shares of the company’s stock valued at $146,000 after buying an additional 2,256 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Constellation Pharmaceuticals in the 4th quarter valued at about $195,000. 55.37% of the stock is currently owned by institutional investors and hedge funds.
CNST stock traded down $0.08 during trading on Friday, hitting $37.60. The company had a trading volume of 204,647 shares, compared to its average volume of 361,996. The firm has a market capitalization of $1.53 billion, a P/E ratio of -11.97 and a beta of 6.93. Constellation Pharmaceuticals has a 52-week low of $6.01 and a 52-week high of $59.49. The company has a 50 day simple moving average of $37.31 and a 200-day simple moving average of $25.30. The company has a quick ratio of 5.19, a current ratio of 5.19 and a debt-to-equity ratio of 0.81.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.
Featured Story: Why do earnings reports matter?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.